Latest Anteotech (ASX:ADO) News

AnteoTech has shipped a 20-litre sample of its new Anteo C primer coating additive to a South Korean manufacturer, marking a key step from lab trials to manufacturing-scale evaluation in lithium-ion battery production.

AnteoTech has locked in an underwriting deal to guarantee up to $7.5 million from the exercise of listed options, potentially raising as much as $10 million before costs.

Battery tech, biotech and balance-sheet repair drove the biggest gains this week, while guidance cuts and weak post-halt trading hurt several names. Deal-making and fresh equity funding stayed busy, especially in rare earths, defence and gold.

AnteoTech has secured independent validation of its Ultranode™ 95 silicon anode in commercial-format battery cells, demonstrating over 40% higher energy density and strong cycle life, advancing its push into the growing drone battery market.

Speculative resources names drove the biggest moves this week, with Patriot Resources, Brazilian Critical Minerals and Rent.com.au leading the gainers. At the other end, Qoria, SQX Resources and 4DMedical fell hard as capital raisings, weak follow-through and post-gap selling hit sentiment.

AnteoTech (ASX: ADO) pushed forward its advanced battery and life sciences technologies in the March 2026 quarter, achieving key product validations and expanding its sales pipeline to record levels. The company ended the period with A$3.3 million cash and no debt following a recent A$3.5 million capital raise.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

AnteoTech has marked significant progress in battery and life sciences sectors, highlighted by a major capital raise and strategic US partnership. The company is poised to convert promising trials into sales amid expanding market opportunities.

AnteoTech has raised A$3.5 million through a discounted share placement to accelerate commercialisation of its advanced battery and life sciences technologies globally. The capital injection supports strategic partnerships and sales expansion in key markets including the US and India.

AnteoTech secures a significant order from the Serum Institute of India and expands its Life Sciences pipeline with new product developments and global partnerships, positioning for accelerated growth in 2026.

AnteoTech has achieved a breakthrough with its Ultranode™ X anode surpassing 1,000 charge cycles at 80% capacity retention, meeting key benchmarks for electric vehicle and eVTOL batteries. This milestone leverages cost-effective silicon materials, promising to reshape supply chains and accelerate market adoption.

AnteoTech Ltd reports strong quarterly progress with a key US joint development agreement, significant manufacturing scale-up, and expanded market access in South Korea, underpinning its 2025 commercialisation strategy.